000756 新华制药
已收盘 11-15 15:00:00
资讯
新帖
简况
11月12日新华制药现1笔大宗交易 机构净买入210.6万元
证券之星 · 11-12
11月12日新华制药现1笔大宗交易 机构净买入210.6万元
新华制药最新公告:非布司他片获得《药品注册证书》
证券之星 · 11-11
新华制药最新公告:非布司他片获得《药品注册证书》
新华制药(000756.SZ):非布司他片获得药品注册证书
智通财经 · 11-11
新华制药(000756.SZ):非布司他片获得药品注册证书
新华制药:非布司他片获药品注册证书
美港电讯 · 11-11
新华制药:非布司他片获药品注册证书
新华制药(000756.SZ):葡萄糖酸钙注射液通过一致性评价
智通财经 · 11-05
新华制药(000756.SZ):葡萄糖酸钙注射液通过一致性评价
新华制药最新公告:葡萄糖酸钙注射液通过仿制药一致性评价
证券之星 · 11-05
新华制药最新公告:葡萄糖酸钙注射液通过仿制药一致性评价
新华制药最新公告:全资子公司新达制药药品通过仿制药一致性评价
证券之星 · 11-04
新华制药最新公告:全资子公司新达制药药品通过仿制药一致性评价
新华制药最新公告:喷他佐辛获得化学原料药上市申请批准通知书
证券之星 · 11-04
新华制药最新公告:喷他佐辛获得化学原料药上市申请批准通知书
新华制药(000756.SZ):头孢呋辛酯分散片通过仿制药质量和疗效一致性评价
智通财经 · 11-04
新华制药(000756.SZ):头孢呋辛酯分散片通过仿制药质量和疗效一致性评价
新华制药(000756.SZ):喷他佐辛获得化学原料药上市申请批准
智通财经 · 11-04
新华制药(000756.SZ):喷他佐辛获得化学原料药上市申请批准
新华制药:头孢呋辛酯分散片通过仿制药一致性评价
美港电讯 · 11-04
新华制药:头孢呋辛酯分散片通过仿制药一致性评价
新华制药(000756)2024年三季报简析:增收不增利
证券之星 · 10-31
新华制药(000756)2024年三季报简析:增收不增利
新华制药最新公告:2024年第三季度净利润同比下降35.60%
证券之星 · 10-29
新华制药最新公告:2024年第三季度净利润同比下降35.60%
默克医药健康在全球体量最大的医药合作项目落户新华制药
市场资讯 · 10-29
默克医药健康在全球体量最大的医药合作项目落户新华制药
新华制药(000756.SZ)发布前三季度业绩,净利润3.44亿元,同比下降12.22%
智通财经 · 10-29
新华制药(000756.SZ)发布前三季度业绩,净利润3.44亿元,同比下降12.22%
新华制药最新公告:获批二羟丙茶碱注射液上市许可变更
证券之星 · 10-28
新华制药最新公告:获批二羟丙茶碱注射液上市许可变更
新华制药最新公告:碳酸司维拉姆片(800mg)简化新药申请获FDA批准
证券之星 · 10-28
新华制药最新公告:碳酸司维拉姆片(800mg)简化新药申请获FDA批准
新华制药(000756.SZ)拟10股派0.25元 于9月27日除权除息
智通财经 · 09-19
新华制药(000756.SZ)拟10股派0.25元 于9月27日除权除息
新华制药最新公告:获得己酮可可碱注射液药品补充申请批准通知书
证券之星 · 09-03
新华制药最新公告:获得己酮可可碱注射液药品补充申请批准通知书
新华制药(000756.SZ)成为己酮可可碱注射液上市许可持有人
智通财经 · 09-03
新华制药(000756.SZ)成为己酮可可碱注射液上市许可持有人
加载更多
公司概况
公司名称:
山东新华制药股份有限公司
所属行业:
医药制造业
上市日期:
1997-08-06
主营业务:
山东新华制药股份有限公司主要从事开发、制造和销售化学原料药、制剂、医药中间体及其他产品。公司的主要产品有解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司拥有技术创新优势,现为高新技术企业、国家火炬计划重点高新技术企业、国家火炬计划生物医药产业基地骨干企业,拥有国家级企业技术中心,建有企业博士后科研工作站。公司被公示为“山东省技术创新示范企业”,被评为山东人才工作先进单位。
发行价格:
3.45
{"stockData":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":16.52,"timestamp":1731654213000,"preClose":16.68,"halted":0,"volume":10055404,"delay":0,"floatShares":449000000,"shares":682000000,"eps":0.6575,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.16,"latestTime":"11-15 15:00:00","open":16.54,"high":16.93,"low":16.52,"amount":168000000,"amplitude":0.0246,"askPrice":16.52,"askSize":636,"bidPrice":16.51,"bidSize":339,"shortable":0,"etf":0,"ttmEps":0.6575,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731893400000},"adr":0,"adjPreClose":16.68,"symbolType":"stock","openAndCloseTimeList":[[1731634200000,1731641400000],[1731646800000,1731654000000]],"highLimit":18.35,"lowLimit":15.01,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":682407635,"pbRate":2.34,"roa":"--","roe":"7.21%","epsLYR":0.74,"committee":-0.415281,"marketValue":11273000000,"floatMarketCap":7414000000,"peRate":25.125474,"changeRate":-0.0096,"turnoverRate":0.0224,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-11-18。"},"requestUrl":"/m/hq/s/000756","defaultTab":"news","newsList":[{"id":"2482727787","title":"11月12日新华制药现1笔大宗交易 机构净买入210.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482727787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482727787?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:46","pubTimestamp":1731401215,"startTime":"0","endTime":"0","summary":"证券之星消息,11月12日新华制药发生大宗交易,交易数据如下:大宗交易成交价格17.55元,成交12万股,成交金额210.6万元,买方营业部为机构专用,卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易,合计成交1200.0手。该股近期无解禁股上市。截至2024年11月12日收盘,新华制药(000756)报收于17.55元,上涨3.36%,换手率9.78%,成交量43.89万手,成交额7.73亿元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111200026801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2482270761","title":"新华制药最新公告:非布司他片获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2482270761","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482270761?lang=zh_cn&edition=full","pubTime":"2024-11-11 17:20","pubTimestamp":1731316826,"startTime":"0","endTime":"0","summary":"新华制药公告,全资子公司新达制药近日收到国家药品监督管理局核准签发的非布司他片《药品注册证书》,批准本品上市许可申请。非布司他片是一种黄嘌呤氧化酶抑制剂,通过抑制尿酸合成降低血清尿酸浓度,适用于具有痛风症状的高尿酸血症的长期治疗。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100022513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2482277471","title":"新华制药(000756.SZ):非布司他片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482277471","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482277471?lang=zh_cn&edition=full","pubTime":"2024-11-11 17:11","pubTimestamp":1731316290,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)发布公告,近日,公司之全资子公司山东淄博新达制药有限公司(“新达制药”)收到国家药品监督管理局核准签发的非布司他片《药品注册证书》,批准本品上市许可申请。据悉,非布司他为2-芳基噻唑衍生物,是一种黄嘌呤氧化酶抑制剂,通过抑制尿酸合成降低血清尿酸浓度,适用于具有痛风症状的高尿酸血症的长期治疗,使用方式为口服。非布司他具有高度选择性,作用强于别嘌醇,主要通过肝脏代谢,不依赖肾排出,对轻中度肾功能不全者安全有效,副作用小,疗效确切。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2482272432","title":"新华制药:非布司他片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482272432","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482272432?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:54","pubTimestamp":1731315294,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1191","01477","BK0164","BK0239","BK1574","000756"],"gpt_icon":0},{"id":"2481522527","title":"新华制药(000756.SZ):葡萄糖酸钙注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481522527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481522527?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:31","pubTimestamp":1730799085,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)公告,公司收到国家药品监督管理局核准签发葡萄糖酸钙注射液(10ml:1g)的《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2481358522","title":"新华制药最新公告:葡萄糖酸钙注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2481358522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481358522?lang=zh_cn&edition=full","pubTime":"2024-11-05 17:29","pubTimestamp":1730798990,"startTime":"0","endTime":"0","summary":"新华制药公告,公司收到国家药品监督管理局核准签发的葡萄糖酸钙注射液(10ml:1g)的《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110500030436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2480237966","title":"新华制药最新公告:全资子公司新达制药药品通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2480237966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480237966?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:01","pubTimestamp":1730710878,"startTime":"0","endTime":"0","summary":"新华制药公告,全资子公司新达制药收到国家药品监督管理局核准签发的头孢呋辛酯分散片《药品补充申请批准通知书》,批准该药品通过仿制药质量和疗效一致性评价。头孢呋辛酯分散片适用于治疗多种感染性疾病,包括急性扁桃体炎、咽炎和急性细菌性鼻窦炎等。该药品已进入国家甲类医保目录、国家基本药物目录,2023年中国城市公立医院头孢呋辛制剂销售额约为15.93亿元。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400021923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK1574","BK0164","01477","BK1191"],"gpt_icon":0},{"id":"2480379934","title":"新华制药最新公告:喷他佐辛获得化学原料药上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2480379934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480379934?lang=zh_cn&edition=full","pubTime":"2024-11-04 17:00","pubTimestamp":1730710838,"startTime":"0","endTime":"0","summary":"新华制药公告,公司近日收到国家药品监督管理局核准签发的喷他佐辛《化学原料药上市申请批准通知书》,本品符合药品注册的有关要求,批准注册。新华制药是国内第3家通过该原料药审批的企业。喷他佐辛属于精麻类药物,适用于各种疼痛,如癌性疼痛、创伤性疼痛、手术后疼痛,也可作为外科手术麻醉的辅助用药。该原料药的获批将进一步丰富公司精麻类产品线,提升公司核心竞争力。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400021926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2480884379","title":"新华制药(000756.SZ):头孢呋辛酯分散片通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2480884379","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480884379?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:59","pubTimestamp":1730710772,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药 发布公告,近日,山东新华制药股份有限公司之全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的头孢呋辛酯分散片《药品补充申请批准通知书》,批准本品通过仿制药质量和疗效一致性评价。据悉,头孢呋辛酯属于第二代头孢菌素类抗生素,是杀菌性头孢菌素类抗生素头孢呋辛的口服前体药,对大多数β-内酰胺酶耐受,可广泛作用于革兰阳性菌和革兰阴性菌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","000756","BK0239"],"gpt_icon":0},{"id":"2480376403","title":"新华制药(000756.SZ):喷他佐辛获得化学原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2480376403","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480376403?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:57","pubTimestamp":1730710623,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)发布公告,近日,公司收到国家药品监督管理局核准签发的喷他佐辛(“本品”)《化学原料药上市申请批准通知书》,经审查,本品符合药品注册的有关要求,批准注册。本公司是国内第3家通过该原料药审批的企业。据悉,上述产品属于精麻类药物,适用于各种疼痛。如癌性疼痛、创伤性疼痛、手术后疼痛,也可用于手术前或麻醉前给药,作为外科手术麻醉的辅助用药。上述产品的获批表明该原料药已符合国家相关药品审评技术标准,已批准在国内制剂中使用,将进一步丰富公司精麻类产品线,提升公司核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2480761603","title":"新华制药:头孢呋辛酯分散片通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2480761603","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480761603?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:54","pubTimestamp":1730710485,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0164","000756","BK0239","BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2479915760","title":"新华制药(000756)2024年三季报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2479915760","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479915760?lang=zh_cn&edition=full","pubTime":"2024-10-31 06:29","pubTimestamp":1730327386,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期新华制药发布2024年三季报。根据财报显示,新华制药增收不增利。截至本报告期末,公司营业总收入67.34亿元,同比上升3.64%,归母净利润3.44亿元,同比下降12.22%。按单季度数据看,第三季度营业总收入20.02亿元,同比上升9.67%,第三季度归母净利润7867.55万元,同比下降35.6%。本次财报公布的各项数据指标表现一般。去年的净利率为6.25%,算上全部成本后,公司产品或服务的附加值一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100008254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0164","000756"],"gpt_icon":0},{"id":"2479149286","title":"新华制药最新公告:2024年第三季度净利润同比下降35.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479149286","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479149286?lang=zh_cn&edition=full","pubTime":"2024-10-29 22:09","pubTimestamp":1730210966,"startTime":"0","endTime":"0","summary":"新华制药发布2024年第三季度报告,第三季度净利润7867.55万元,同比下降35.60%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900041744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756"],"gpt_icon":0},{"id":"2479285505","title":"默克医药健康在全球体量最大的医药合作项目落户新华制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2479285505","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479285505?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:16","pubTimestamp":1730207760,"startTime":"0","endTime":"0","summary":"10月29日,新华制药与默克医药健康举行格华止项目商业化启动仪式,默克集团在山东首个医药合作项目、默克医药健康在全球范围内体量最大的医药合作项目落户新华制药。默克中国医药健康董事、总经理张巍,默克集团副总裁Stephane Piquand,新华制药党委书记、董事长贺同庆等共同参加系列活动。本次强强联手,将进一步加速新华制药国际化进程。未来的新华制药,发展值得期待!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2024-10-29/doc-incufuvt7523776.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-10-29/doc-incufuvt7523776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1116320737.USD","LU1934455863.HKD","IE0002141913.USD","BK1515","LU0208291251.USD","IE00BSNM7G36.USD","LU0965509101.SGD","LU0965509283.SGD","000756","BK0164","BK1574","LU1023059063.AUD","LU0203345920.USD","LU0106261372.USD","LU1066053197.SGD","IE00BJT1NW94.SGD","IE00B1BXHZ80.USD","LU1917777945.USD","LU0265550359.USD","LU0985320562.USD","BK4534","BK0239","BK1161","LU0122379950.USD","IE00BJJMRZ35.SGD","BK4585","LU0861579265.USD","BK4516","09939","LU1061106388.HKD","LU1934455194.USD","LU1934455277.USD","159938","LU0203347892.USD","LU0238689110.USD","LU0211331839.USD","LU1037948897.HKD","LU1066051811.HKD","BK4588","LU1093756168.USD","LU1037948541.HKD","LU1430594728.SGD","LU0965508806.USD","LU0058720904.USD","MRK","LU0006306889.USD","BK4533","IE0009355771.USD","IE00B4R5TH58.HKD","LU1291159041.SGD"],"gpt_icon":0},{"id":"2479090384","title":"新华制药(000756.SZ)发布前三季度业绩,净利润3.44亿元,同比下降12.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479090384","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479090384?lang=zh_cn&edition=full","pubTime":"2024-10-29 20:23","pubTimestamp":1730204601,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)发布2024年三季度报告,前三季度,公司实现营业收入67.34亿元,同比增长3.64%。归属于上市公司股东的净利润3.44亿元,同比下降12.22%。归属于上市公司股东的扣除非经常性损益的净利润3.21亿元,同比下降11.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1202809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756"],"gpt_icon":0},{"id":"2478163105","title":"新华制药最新公告:获批二羟丙茶碱注射液上市许可变更","url":"https://stock-news.laohu8.com/highlight/detail?id=2478163105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478163105?lang=zh_cn&edition=full","pubTime":"2024-10-28 19:01","pubTimestamp":1730113295,"startTime":"0","endTime":"0","summary":"新华制药公告,公司收到国家药品监督管理局核准签发的二羟丙茶碱注射液药品补充申请批准通知书》,批准本品上市许可持有人转让补充申请。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800026235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0164","BK0239","000756"],"gpt_icon":0},{"id":"2478179741","title":"新华制药最新公告:碳酸司维拉姆片(800mg)简化新药申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2478179741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478179741?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:09","pubTimestamp":1730106572,"startTime":"0","endTime":"0","summary":"新华制药公告,公司收到美国食品药品监督管理局(FDA)签发的碳酸司维拉姆片(800mg)简化新药申请(ANDA)批准函。该药品用于控制正在接受透析治疗的慢性肾脏病(CKD)成人患者的高磷血症。此次ANDA获得批准并生效,有助于公司拓宽国外市场,提升市场竞争力。但药品销售业务易受医药行业政策变动、市场环境变化等因素影响,存在不确定性。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800023065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000756","BK0164"],"gpt_icon":0},{"id":"2468525919","title":"新华制药(000756.SZ)拟10股派0.25元 于9月27日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2468525919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468525919?lang=zh_cn&edition=full","pubTime":"2024-09-19 17:24","pubTimestamp":1726737888,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药(000756.SZ)公告,公司2024年半年度A股派息拟:每10股派发现金人民币0.25元(含税)。除权除息日为2024年9月27日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000756","BK0239","BK0164"],"gpt_icon":0},{"id":"2464820265","title":"新华制药最新公告:获得己酮可可碱注射液药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2464820265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464820265?lang=zh_cn&edition=full","pubTime":"2024-09-03 17:31","pubTimestamp":1725355884,"startTime":"0","endTime":"0","summary":"新华制药公告,公司近日收到国家药监局核准签发的己酮可可碱注射液《药品补充申请批准通知书》,批准该药品上市许可持有人转让补充申请。公司成为该药品的上市许可持有人。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090300029496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000756","BK0164","BK0239"],"gpt_icon":0},{"id":"2464270818","title":"新华制药(000756.SZ)成为己酮可可碱注射液上市许可持有人","url":"https://stock-news.laohu8.com/highlight/detail?id=2464270818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464270818?lang=zh_cn&edition=full","pubTime":"2024-09-03 17:23","pubTimestamp":1725355429,"startTime":"0","endTime":"0","summary":"智通财经APP讯,新华制药 发布公告,近日,公收到国家药品监督管理局核准签发的己酮可可碱注射液《药品补充申请批准通知书》,批准本品上市许可持有人转让补充申请。己酮可可碱注射液通过国家药品监督管理局审批,新华制药成为本品的上市许可持有人。据相关数据显示,2023年中国城市公立医院己酮可可碱销售额达人民币9.7亿元,比2022年增长11.98%,其中注射剂型销售额达人民币7.4亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1178689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0164","BK0239","000756"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1997-08-06","address":"山东省淄博市张店区高新技术产业开发区化工区","stockEarnings":[{"period":"1week","weight":-0.0161},{"period":"1month","weight":0.0644},{"period":"3month","weight":0.0375},{"period":"6month","weight":0.0263},{"period":"1year","weight":-0.2093},{"period":"ytd","weight":-0.1737}],"companyName":"山东新华制药股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"68240万元","compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.0399},{"period":"3month","weight":0.1567},{"period":"6month","weight":0.056},{"period":"1year","weight":0.0917},{"period":"ytd","weight":0.1196}],"survey":" 山东新华制药股份有限公司主要从事开发、制造和销售化学原料药、制剂、医药中间体及其他产品。公司的主要产品有解热镇痛类原料药、片剂、针剂、胶囊剂、医药中间体。公司拥有技术创新优势,现为高新技术企业、国家火炬计划重点高新技术企业、国家火炬计划生物医药产业基地骨干企业,拥有国家级企业技术中心,建有企业博士后科研工作站。公司被公示为“山东省技术创新示范企业”,被评为山东人才工作先进单位。","serverTime":1731802730436,"listedPrice":3.45,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新华制药,000756,新华制药股票,新华制药股票老虎,新华制药股票老虎国际,新华制药行情,新华制药股票行情,新华制药股价,新华制药股市,新华制药股票价格,新华制药股票交易,新华制药股票购买,新华制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新华制药(000756)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新华制药(000756)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}